Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 3;9(11):10175-10183.
doi: 10.18632/oncotarget.23699. eCollection 2018 Feb 9.

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression

Gregorio J Petrirena  1 , Julien Masliah-Planchon  2   3 , Quentin Sala  4 , Bertrand Pourroy  5 , Didier Frappaz  6 , Emeline Tabouret  1   7 , Thomas Graillon  8 , Jean-Claude Gentet  9 , Olivier Delattre  2   3 , Olivier Chinot  1   7 , Laetitia Padovani  10
Affiliations

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression

Gregorio J Petrirena et al. Oncotarget. .

Abstract

Background: Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB).

Materials and methods: Clinical and PET/CT findings during treatment with successive hedgehog antagonists and temozolomide monotherapies are described in a heavily pre-treated patient with recurrent extraneural metastases from PTCH1 mutated/ wild type smoothened (SMO) CNS SHH-MB. Molecular tests were prospectively performed in tissue from two extraneural sites at progression.

Results: Sustained clinical/metabolic response was obtained to vismodegib. At progression, itraconazole was ineffective, but salvage temozolomide treatment results in a response similar to vismodegib. At further progression, acquired SMO and PIK3CA mutations were identified in bone (G477L and H1047A, respectively) and epidural (L412P and H1065L, respectively) metastases. No response was observed with subsequent sonidegib treatment.

Conclusions: This is the first clinical report of recurrent extraneural PTCH1 mutated SHH-MB exhibiting: 1) a sustained response to vismodegib and temozolomide, and 2) inter-metastatic molecular heterogeneity and acquired SMO-G477L, SMO-L412P, and PIK3CA-H1065L mutations at progression, highlighting the need for a multitarget treatment approach.

Keywords: PIK3CA mutation; smoothened mutation; sonic hedgehog medulloblastoma; temozolomide; vismodegib.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest are disclosed. All the authors read and approved the final version of the manuscript prior to submission.

Figures

Figure 1
Figure 1
Whole body projections from F18–fluorodeoxyglucose PET scans showing (A) baseline examination before vismodegib, (B) partial response to vismodegib, (C) disease progression under vismodegib, (D) further progression under itraconazole, (E) partial response to temozolomide, (F) progression under temozolomide, and (G) progression after sonidegib with response in 6th thoracic and 3rd lumbar locally treated lesions.
Figure 2
Figure 2. Axial F18–fluorodeoxyglucose PET/CT images at the pelvic level showing the right sacral alae lesion (arrow) chosen as a target for molecular analyses after progression to temozolomide
(A) Before vismodegib monotherapy, (B) partial response to vismodegib, (C) disease progression under vismodegib, (D) further lesion size progression under itraconazole, (E) partial response to temozolomide, and (F) progression under temozolomide when the CT scan-guided biopsy was performed (F’).
Figure 3
Figure 3. PTCH1 (top-left), SMO (top-right), and PIK3CA (bottom) sequence analysis in the primary CNS tumor and two extraneural metastases after progression to vismodegib and temozolomide
Figure 4
Figure 4
(A) Thoracic epidural metastasis (arrow) detected on PET/CT at progression under temozolomide. T2-weighted MRI scan of the spine at (B) baseline, (C) ten days after starting sonidegib showing tumor progression, and (D) after surgical decompression (raw sagittal and axial images on top and bottom, respectively).
See this image and copyright information in PMC

References

    1. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol. 2012;8:340–51. https://doi.org/10.1038/nrneurol.2012.78. - DOI - PubMed
    1. Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2646–54. https://doi.org/10.1200/JCO.2014.60.1591. - DOI - PMC - PubMed
    1. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L, Holcomb T, Stinson J, Gould SE, Coleman B, LoRusso PM, Von Hoff DD, de Sauvage FJ, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–8. https://doi.org/10.1056/NEJMoa0902903. - DOI - PMC - PubMed
    1. Asklund T, Henriksson R, Axelsson J, Bergström Å, Kasper M, Ögren M, Toftgård R, Riklund KÅ. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma. Acta Oncol Stockh Swed. 2013;52:862–6. https://doi.org/10.3109/0284186X.2012.724537. - DOI - PubMed
    1. Young RJ, Khakoo Y, Yhu S, Wolden S, De Braganca KC, Gilheeney SW, Dunkel IJ. Extraneural metastases of medulloblastoma: desmoplastic variants may have prolonged survival. Pediatr Blood Cancer. 2015;62:611–5. https://doi.org/10.1002/pbc.25354. - DOI - PubMed

LinkOut - more resources